This inventor holds 6 USPTO granted patents. Top assignees: Yamanouchi Pharmaceutical Company Ltd., Rational Drug Design Laboratories, Other. Active years: 1987-2005.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Tokyo, JP (1987 - 1989)
- Nakano, Nakano-ku, Tokyo, JP (1990)
- Itabashi-ku, JP (2005)
Company Filing History:
5 out of 329 
1 out of 6 
1 out of 834,570 Years Active: 1987-2005
Title: Shunji Kageyama: Innovator in Pharmaceutical Chemistry
Introduction
Shunji Kageyama is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 6 patents to his name, Kageyama's work has the potential to impact various medical treatments.
Latest Patents
One of Kageyama's latest inventions is an amide derivative, which is characterized as an N-({[4-(substituted thiazol-4-yl)phenyl]carbamoyl}methyl)amide derivative. This compound features an aryl or heteroaryl group directly substituted on the N atom of the amido group. The amide derivative exhibits excellent anti-herpesvirus action, making it useful as a medicament and antiviral agent. It serves as a preventive or therapeutic agent for diseases associated with Herpesviridae virus infections, including varicella (chickenpox), shingles, labial herpes, herpes encephalitis, and genital herpes.
Another significant patent involves certain thiazol-4-yl-phenoxy derivatives that possess lipid-lowering properties. These derivatives, along with pharmaceutical compositions containing them, are beneficial for lowering lipid activity in subjects, thereby aiding in the reduction of cholesterol and triglycerides.
Career Highlights
Kageyama has worked with prominent organizations in the pharmaceutical industry, including Yamanouchi Pharmaceutical Company Ltd. and Rational Drug Design Laboratories. His experience in these companies has allowed him to refine his skills and contribute to innovative drug development.
Collaborations
Throughout his career, Kageyama has collaborated with esteemed colleagues such as Tadao Kojima and Minoru Okada. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.
Conclusion
Shunji Kageyama's contributions to pharmaceutical chemistry through his innovative patents demonstrate his commitment to advancing medical science. His work in developing effective antiviral agents and lipid-lowering compounds highlights the importance of innovation in addressing health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile